OSE Immuno: new positive phase 1/2 data
These results, presented at the ESMO congress dedicated to targeted cancer therapies currently taking place in Paris, notably show a good pharmacokinetic and pharmacodynamic profile.
They also show an acceptable safety profile, in line with previous anti-PD1 development, and a high efficacy signal in the first 20 patients representing 13 different tumor types, OSE points out.
Four ongoing partial responses, at a dose of 600 mg every six weeks with a response rate of 36%, have been confirmed in patients with anal squamous cell carcinoma, undifferentiated pleomorphic sarcoma, oncocytic thyroid cancer and alveolar soft-tissue sarcoma.
Following these announcements, OSE Immunotherapeutics shares gained over 5% on Tuesday on the Paris Bourse.
OSE-279 is a humanized anti-PD1 monoclonal antibody that blocks both PD-L1 and PD-L2 ligands, overexpressed in tumor cells and the tumor microenvironment.
As a reminder, OSE Immuno's objective is to develop an anti-PD-1 to address, as a priority, niche indications not targeted by Big Pharmas", say analysts at Invest Securities.
Final results from this Phase I/II trial are expected in the third quarter of 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction